Obecabtagene autoleucel (obe-cel)
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Key Facts
About Autolus Therapeutics
Autolus Therapeutics is a UK-based biotech focused on developing advanced, programmed CAR T-cell therapies with the goal of delivering life-changing benefits to patients. Its most advanced asset, obecabtagene autoleucel (obe-cel), has demonstrated compelling clinical data in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and is progressing through late-stage development. The company's strategy hinges on its proprietary technology platform to create differentiated products, vertical integration for manufacturing control, and expansion into solid tumors and autoimmune diseases to build a diversified pipeline.
View full company profileAbout Autolus Therapeutics
Autolus Therapeutics is a UK-based biotech focused on developing advanced, programmed CAR T-cell therapies with the goal of delivering life-changing benefits to patients. Its most advanced asset, obecabtagene autoleucel (obe-cel), has demonstrated compelling clinical data in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and is progressing through late-stage development. The company's strategy hinges on its proprietary technology platform to create differentiated products, vertical integration for manufacturing control, and expansion into solid tumors and autoimmune diseases to build a diversified pipeline.
View full company profileTherapeutic Areas
Other Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Drugs
| Drug | Company | Phase |
|---|---|---|
| Meta10-19 | Leman Biotech | Phase 1/2 |
| TBI-1501 | Takara Bio | Phase I/II |